Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03030404 · ClinicalTrials.gov registry record
Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 733
- Enrollment target
NCT03030404: Completed study, sponsored by National Cancer Institute (NCI).
NCT03030404 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 733 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03030404 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 733 participants
- Enrollment target
Study Summary
Background: Gastric cancers are cancers of the stomach. Hereditary ones are passed from parent to child. Researchers want to gather data about hereditary gastric cancers. They want to learn about changes these cause in the body and about the genes involved. Objective: -To gather data about hereditary gastric cancer. Eligibility: * People at least 2 years old with personal or family history with a hereditary gastric cancer. * People at least 2 years old with gene changes that lead to such cancer or a lesion that may be hereditary. Design: * Participants will be screened in a separate protocol. * Participants will have: * Physical exam * Medical history * Blood tests * Scans * Photos of skin lesions and other findings * Gynecology consultation for women * Cheek swab (some participants) * For some participants, their relatives will be asked to join the study. * Some participants will be asked to allow the study to get stored tissue samples for relatives who have died. * Some samples will be sent to outside labs. All personal data will be protected. Samples will be destroyed when the study ends. * Participants will get the results of genetic testing. * Participants who cannot come to the NIH clinic may just give a cheek swab and have genetic testing done. * Some participants will be contacted for more testing.
Primary Outcome
Characterization of the natural and clinical histories of hereditary gastric cancer syndromes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 733 participants |
| Start Date | 2017-01-27 |
| Est. Completion | 2025-03-31 |
What the finished NCT03030404 record still lists
NCT03030404 is an observational study that tracks outcomes without assigning an intervention. The registered 733 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03030404 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03030404 about?
NCT03030404 is a clinical study titled "Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer". Background: Gastric cancers are cancers of the stomach. Hereditary ones are passed from parent to child. Researchers want to gather data about hereditary gastric cancers. They want to learn about changes these cause in the body and about the genes involved. Objective: -To gather data about heredi...
What is the current status of trial NCT03030404?
This trial is currently completed. The enrollment target is 733 participants. The study started on 2017-01-27. Estimated completion is 2025-03-31.
Who is sponsoring clinical trial NCT03030404?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06216301 · 734 participants · Phase 3
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- NCT07231419 · 734 participants · Phase 3
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
- NCT05947851 · 735 participants · Phase 3
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- NCT05999084 · 735 participants
Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI